In silico-designed mutations increase variable new-antigen receptor single-domain antibodies for VEGF(165) neutralization

The stability, binding, and tissue penetration of variable new-antigen receptor (VNAR) single-domain antibodies have been tested as part of an investigation into their ability to serve as novel therapeutics. V13 is a VNAR that recognizes vascular endothelial growth factor 165 (VEGF(165)). In the pre...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Oncotarget
मुख्य लेखकों: Millán-Gómez, Dalia, Dueñas, Salvador, Muñoz, Patricia L. A., Camacho-Villegas, Tanya, Elosua, Carolina, Cabanillas-Bernal, Olivia, Escalante, Teresa, Perona, Almudena, Abia, David, Drescher, Florian, Fournier, Pierrick G. J., Ramos, Marco A., Mares, Rosa E., Paniagua-Solis, Jorge, Mata-Gonzalez, Teresa, Gonzalez-Canudas, Jorge, Hoffman, Robert M., Licea-Navarro, Alexei, Sánchez-Campos, Noemí
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Impact Journals LLC 2018
विषय:
Research Paper
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6021326/
https://ncbi.nlm.nih.gov/pubmed/29963259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25549
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन